Tenvie Therapeutics is purpose-built to design and develop small-molecule therapeutics with a focus on neurological diseases. The company advances a pipeline of wholly owned, highly brain-penetrant and precision-designed, peripherally restricted small molecules addressing inflammation, metabolic dysfunction, and lysosomal function. Its most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development across neurological, cardiometabolic, and ophthalmic indications. Tenvie highlights a proven team of CNS drug developers and a diverse portfolio intended to rapidly deliver multiple clinical assets. The company raised $200M and intends to use the funds to accelerate its growth and development efforts. Tenvie’s board includes executives and partners from ARCH Venture Partners, F-Prime Capital, Mubadala Capital and Denali Therapeutics, reflecting investor and industry engagement.

Total raised

$200M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2025